Enzyme Inhibitors

Vutiglabridin View larger

Vutiglabridin

AT61268

CAS 1800188-47-9

More details

Molarity Calculation Cart®

HOW TO ORDER

$85.00

$85.00 per mg

Quantity Discount Table - Order More To Get More Price Discount

QuantitymgUnit Price ($/mg or $/Unit)Final Price
1100 $38.25 Total: $3,825.00
150 $44.20 Total: $2,210.00
125 $51.85 Total: $1,296.25
110 $61.20 Total: $612.00
15 $72.25 Total: $361.25

Data sheet

Molecular FormulaC22H26O4
Molecular Weight354.44
CAS Numbers1800188-47-9
Storage Condition0C Short Term, -20C Long Term
SolubilityDMSO
Purity98% by HPLC
SMILES CodeCC1(C)OC2=C(C3=C(CC(CO3)C4=C(O)C=C(OCC)C=C4)C=C2)CC1
ReferencesBae IY, et al. Species Differences in Stereoselective Pharmacokinetics of HSG4112, A New Anti-Obesity Agent. Pharmaceutics. 2020;12[2] 127.

More info

Vutiglabridin (HSG4112) is a novel and safe modulator of PON2, a racemic compound. vutiglabridin is an optimized structural analogue of Glabridin and is superior to Glabridin in terms of weight loss and chemical stability. vutiglabridin ameliorates mptp-induced neurodegeneration in Parkinson's disease mice by targeting mitochondrial paraoxonase-2. Vutiglabridin is a clinical phase 2 drug for the treatment of obesity and has therapeutic effects on p-mitochondrial PON2 in a PD model. vutiglabridin penetrates the brain, binds PON2, and restores 1-methyl-4-phenylpyridine (MPP*)-induced neuroblastoma in SH-SY5Y Vutiglabridin significantly attenuated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dyskinesia and dopaminergic neuronal damage in mice modeled with PD in mouse experiments.